Business
Appointment of Joint Broker
Appointment of Joint Broker.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n \n \n 20 July 2022\n \n \n \n \n \n \n \n \n Roquefort Therapeutics plc\n \n \n \n (\"Roquefort Therapeutics\" or the \"Company\")\n \n \n \n \n \n \n \n Appointment of Joint Broker\n \n \n \n \n \n \n \n Roquefort Therapeutics (LSE:ROQ,OTCQB:ROQAF), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce the appointment of Hybridan LLP (\"Hybridan\") as its Joint Broker with immediate effect.\n \n \n \n \n \n \n Stephen West, Roquefort Therapeutics Executive Chairman, commented:\n \n \n \n \n \"We are delighted to be working with Hybridan going forward. Hybridan has a deep understanding of the life sciences sector particularly within small caps, and their experience will be invaluable to Roquefort Therapeutics as we target further institutional investors and family offices.\"\n \n \n \n \n \n \n \n \n \n -Ends-\n \n \n \n \n \n \n \n \n \n Enquiries:\n \n \n \n \n \n \n \n Roquefort Therapeutics plc\n \n \n \n \n \n \n \n Stephen West (Chairman)\n \n \n \n \n +44 (0)20 3290 9339\n \n \n \n \n \n \n \n \n \n \n Hybridan LLP (Joint Broker)\n \n \n \n Claire Louise Noyce\n \n \n \n \n \n \n \n \n Optiva Securities Limited (Joint Broker)\n \n \n \n \n \n \n \n \n +44 (0)203 764 2341\n \n \n \n \n \n \n Christian Dennis\n \n \n \n \n \n \n Buchanan (Public Relations)\n \n \n \n Ben Romney / Jamie Hooper / George Beale\n \n \n \n \n \n \n \n +44 (0)20 3411 1881\n \n \n \n \n \n \n \n \n +44 (0)20 7466 5000\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n For further information on Roquefort Therapeutics, please\n visit\n \n www.roquefortplc.com\n \n and\n @RoquefortTherap\n on Twitter.\n \n \n \n \n \n LEI: 254900P4SISIWOR9RH34\n \n \n \n \n About Roquefort Therapeutics\n \n \n \n Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company is focused on developing first in class Midkine inhibiting drugs for the treatment of cancer. \n \n \n \n \n \n Through extensive research resulting in validation through publication in over 1,000 scientific publications, Roquefort Therapeutics has identified the...